Vanguard Group’s Entasis Therapeutics Holdings Inc. ETTX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q3 | – | Sell |
-502,622
| Closed | -$1.11M | – | 4656 |
|
|
2022
Q2 | $1.11M | Buy |
502,622
+18,899
| +4% | +$37.7K | ﹤0.01% | 4055 |
|
|
2022
Q1 | $905K | Buy |
483,723
+33,768
| +8% | +$61.5K | ﹤0.01% | 4239 |
|
|
2021
Q4 | $986K | Buy |
449,955
+23,720
| +6% | +$64.1K | ﹤0.01% | 4269 |
|
|
2021
Q3 | $1.42M | Buy |
426,235
+6,238
| +1% | +$16.9K | ﹤0.01% | 4160 |
|
|
2021
Q2 | $1.12M | Buy |
419,997
+214,831
| +105% | +$485K | ﹤0.01% | 4126 |
|
|
2021
Q1 | $439K | Buy |
205,166
+72,007
| +54% | +$205K | ﹤0.01% | 4153 |
|
|
2020
Q4 | $329K | Buy |
133,159
+34,400
| +35% | +$67.6K | ﹤0.01% | 4028 |
|
|
2020
Q3 | $201K | Buy |
98,759
+44,233
| +81% | +$126K | ﹤0.01% | 3954 |
|
|
2020
Q2 | $161K | Hold |
54,526
| – | – | ﹤0.01% | 3944 |
|
|
2020
Q1 | $144K | Hold |
54,526
| – | – | ﹤0.01% | 3904 |
|
|
2019
Q4 | $271K | Hold |
54,526
| – | – | ﹤0.01% | 3901 |
|
|
2019
Q3 | $318K | Buy |
54,526
+5,429
| +11% | +$36.4K | ﹤0.01% | 3890 |
|
|
2019
Q2 | $317K | Hold |
49,097
| – | – | ﹤0.01% | 3896 |
|
|
2019
Q1 | $332K | Hold |
49,097
| – | – | ﹤0.01% | 3835 |
|
|
2018
Q4 | $200K | Buy |
+49,097
| New | +$323K | ﹤0.01% | 3906 |
|
Vanguard Group's ETTX Position: Q3 2022 in Review
Vanguard Group sold out of Entasis Therapeutics Holdings Inc. (ETTX) in Q3 2022, closing a stake of 502,622 shares — an estimated $1.11M sold.
Vanguard Group first reported a position in ETTX in Q4 2018 and held it in 15 quarters. The position peaked at $1.42M in Q3 2021. 0 funds tracked by Wall St. Rank hold ETTX as of Q3 2022.
- Vanguard Group reported no remaining Entasis Therapeutics Holdings Inc. position as of Q3 2022 after selling out during the quarter.
- Vanguard Group sold 502,622 Entasis Therapeutics Holdings Inc. shares in Q3 2022, an estimated $1.11M.
- Vanguard Group first reported a position in Entasis Therapeutics Holdings Inc. in Q4 2018 and held it in 15 quarters.
- Vanguard Group's Entasis Therapeutics Holdings Inc. position peaked at $1.42M in Q3 2021.
- 0 funds tracked by Wall St. Rank held Entasis Therapeutics Holdings Inc. as of Q3 2022.
Based on Vanguard Group's 13F filing for Q3 2022, filed 14 Nov 2022.